The researchers also determined that MS patients that have lower miR-155 and miR-26A levels after 6 months of treatment simultaneously present lower IL-17 and TNF-α levels, but no impact upon IFN-γ and IL-6 secretion was noted. Here, IL17A is linked to myeloid sarcoma.